Classification Term: 3742
N-glucuronides (ontology term: CHEMONTID:0002814)
Glucuronides in which the aglycone is linked to the carbohydrate unit through a N-glycosidic bond." []
found 10 associated metabolites at no_class-level_8 metabolite taxonomy ontology rank level.
Ancestor: Glucuronides
Child Taxonomies: There is no child term of current ontology term.
Phenethylamine glucuronide
Phenethylamine glucuronide is a natural human metabolite of Phenethylamine generated in the liver by UDP glucuonyltransferase. Glucuronidation is used to assist in the excretion of toxic substances, drugs or other substances that cannot be used as an energy source. Glucuronic acid is attached via a glycosidic bond to the substance, and the resulting glucuronide, which has a much higher water solubility than the original substance, is eventually excreted by the kidneys. Phenethylamine glucuronide is a natural human metabolite of Phenethylamine generated in the liver by UDP glucuonyltransferase.
Sulfamethoxazole N1-glucuronide
Sulfamethoxazole N1-glucuronide is a metabolite of Sulfamethoxazole. Sulfamethoxazole n1-glucuronide belongs to the family of Phenols and Derivatives. These are compounds containing a phenol moiety, which is a benzene bearing an hydroxyl group.
N6-Galacturonyl-L-lysine
N6-Galacturonyl-L-lysine is found in garden tomato. N6-Galacturonyl-L-lysine is a possible constituent of plant cell walls including tomato and spinach. Possible constituent of plant cell walls including tomato and spinach. N6-Galacturonyl-L-lysine is found in green vegetables and garden tomato.
Ketotifen-N-glucuronide
C25H27NO7S (485.15081520000007)
Ketotifen-N-glucuronide is a metabolite of ketotifen. Ketotifen is a second-generation H1-antihistamine and mast cell stabilizer. It is most commonly sold in as a salt of fumaric acid, ketotifen fumarate, and is available in two forms. In its ophthalmic form, it is used to treat allergic conjunctivitis, or the itchy red eyes caused by allergies. In its oral form, it is used to prevent asthma attacks. Side effects include drowsiness, weight gain, dry mouth, irritability, and increased nosebleeds. (Wikipedia)
Fluoxetine glucuronide
C23H26F3NO7 (485.16612820000006)
Fluoxetine glucuronide is a metabolite of fluoxetine. Fluoxetine (also known by the tradenames Prozac, Sarafem, Fontex, among others) is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. Fluoxetine was first documented in 1974 by scientists from Eli Lilly and Company. It was presented to the U.S. Food and Drug Administration in February 1977, with Eli Lilly receiving final approval to market the drug in December 1987. Fluoxetine went off-patent in August 2001 (Wikipedia).
Sorafenib beta-D-Glucuronide
Sorafenib beta-D-Glucuronide is a metabolite of sorafenib. Sorafenib (co-developed and co-marketed by Bayer and Onyx Pharmaceuticals as Nexavar), is a drug approved for the treatment of primary kidney cancer and advanced primary liver cancer. (Wikipedia)
Dihydroartemisinin (DHA)
Dihydroartemisinin (DHA) is a metabolite of artemether. Artemether is an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria. It is combined with Lumefantrine and sold by Novartis under the brand names Riamet and Co-Artem. (Wikipedia)
lamotrigine-2-N-glucuronide
lamotrigine-2-N-glucuronide is a metabolite of lamotrigine. Lamotrigine, marketed in the US and most of Europe as Lamictal by GlaxoSmithKline, is an anticonvulsant drug used in the treatment of epilepsy and bipolar disorder. It is also used as an adjunct in treating depression, though this is considered off-label usage. For epilepsy, it is used to treat focal seizures, primary and secondary tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome. (Wikipedia)
Norfluoxetine glucuronide
Norfluoxetine glucuronide is a metabolite of fluoxetine. Fluoxetine (also known by the tradenames Prozac, Sarafem, Fontex, among others) is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. Fluoxetine was first documented in 1974 by scientists from Eli Lilly and Company. It was presented to the U.S. Food and Drug Administration in February 1977, with Eli Lilly receiving final approval to market the drug in December 1987. Fluoxetine went off-patent in August 2001 (Wikipedia).